Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Australian Study Questions Efficacy Of Bone Cement Treatment

This article was originally published in PharmAsia News

Executive Summary

An Australian study raises serious questions about the efficacy of a popular treatment for osteoporosis. The study conducted by Australian institutions looked into the value of covering percutaneous vertebroplasty under the Medicare Benefits Scheme. The study concluded that after six months of testing the treatment against a placebo treatment, both sets of patients improved by the same degree. The research also raised the possibility the treatment involving injecting bone cement into broken vertebrae might even do more harm than good because of risks involved. (Click here for more

You may also be interested in...



Kite Readies A Second CAR-T For Filing As CD19 Competition Grows

The Gilead subsidiary presented updated data at ASH for its first CD19-targeting CAR-T Yescarta and pivotal results for KTE-X19, which it plans to submit for US FDA approval in mantle cell lymphoma this year. 

US FDA Could Use More Foreign Investigators If It Could Find Them, Woodcock Says

Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.

Supreme Court Doesn't Bite On Amarin Appeal In Omega-3 Fair Trade Complaint

The court included its decision on Amarin’s ’s petition for a writ of certiorari among the single-line denials of nearly 200 appeals to consider decisions in civil litigation and convictions in criminal cases. However, Amarin still eyes curbing competition from omega-3 supplements.

UsernamePublicRestriction

Register

SC072673

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel